Heart transplantation in systemic (AL) amyloidosis: A retrospective study of eight French patients

Archives of Cardiovascular Diseases

Volumn 101, Issue 9, 2008, Pages 523-532

  Mignot, Aude ^a   Varnous, Shaida ^b   Redonnet, Michel ^c   Jaccard, Arnaud ^d   Epailly, Éric ^e   Vermes, Emmanuelle ^f   Boissonnat, Pascale ^g   Gandjbakhch, Iradj ^b   Herpin, Daniel ^a   Touchard, Guy ^a   Bridoux, Frank ^a,h  

^a UNIVERSITÉ DE POITIERS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF LIMOGES   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h University of Poitiers   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; LIGHT CHAIN; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 57849120727     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.06.018     Document Type: Article

References (21)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60.
3. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999;93:1062-6.
4. Conner R, Hosenpud JD, Norman DJ, Pantely GA, Cobanoglu A, Starr A. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant 1988;7:165-7.
5. Valantine HA, Billingham ME. Recurrence of amyloid in a cardiac allograft four months after transplantation. J Heart Transplant 1989;8:337-41.
6. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991;84:III338-43.
7. Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long-term results of heart transplantation in patients with amyloid heart disease. Heart 2001;85:202-7.
8. Kpodonu J, Massad MG, Caines A, Geha SS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24:1763-5.
9. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004;23:1142-53.
10. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107:1227-9.
11. Sack FU, Kristen A, Goldschmidt H, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33:257-62.
12. Thaunat O, Alyanakian MA, Varnous S, et al. Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis. Bone Marrow Transplant 2005;35:419-20.
13. Mignot A, Bridoux F, Thierry A, et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008;93: e32-5.
14. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.
15. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
16. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8.
17. Goodman NJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417-25.
18. Sanchorawala V, Seldin DC, Magnani B, Skinner R, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005;36: 597-600.
19. Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007;83:539-45.
20. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
21. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-93.